February 21, 2022 0 Comments

Journal: Journal of Cellular and Molecular Medicine

February/18/2022
Damage to normal tissue can occur over a long period after cancer radiotherapy. Free radical by radiation can initiate or accelerate chronic inflammation, which can lead to atherosclerosis. However, the underlying mechanisms remain unclear. Vascular smooth muscle cells (VSMCs) proliferate in response to JAK/STAT3 signalling. C-reactive protein (CRP) can induce VSMCs apoptosis via triggering NADPH oxidase (NOX). Apoptotic VSMCs promote instability and inflammation of atherosclerotic lesions. Herein, we identified a VSMCs that switched from proliferation to apoptosis through was enhanced by radiation-induced CRP. NOX inhibition using lentiviral sh-p22phox prevented apoptosis upon radiation-induced CRP. CRP overexpression reduced the amount of STAT3/Ref-1 complex, decreased JAK/STAT phosphorylation and formed a new complex of Ref-1/CRP in VSMC. Apoptosis of VSMCs was further increased by CRP co-overexpressed with Ref-1. Functional inhibition of NOX or p53 also prevented apoptotic activity of the CRP-Ref-1 complex. Immunofluorescence showed co-localization of CRP, Ref-1 and p53 with α-actin-positive VSMC in human atherosclerotic plaques. In conclusion, radiation-induced CRP increased the VSMCs apoptosis through Ref-1, which dissociated the STAT3/Ref-1 complex, interfered with JAK/STAT3 activity, and interacted with CRP-Ref-1, thus resulting in transcription-independent cell death via p53. Targeting CRP as a vascular side effect of radiotherapy could be exploited to improve curability.
Journal: Immunity and Ageing

February/17/2022
Background: Chronic inflammation might play a major role in the pathogenesis linking diabetes mellitus (DM) to cognition. In addition, DM might be the main driver of dementia risk. The purpose of the present study was to evaluate whether inflammation, glycation, or both are associated with the risk of developing all-cause dementia (ACD).
Methods: A nationwide population-based cohort study was conducted with 4113 participants. The data were obtained from the Taiwanese Survey on Prevalence of Hypertension, Hyperglycemia, and Hyperlipidemia (TwSHHH) in 2007, which was linked with the Taiwan National Health Insurance Research Database (NHIRD). The markers of inflammation, expressed as hs-CRP, and glycation, presented as HbA1c, were measured. High levels of hs-CRP and HbA1c were defined as values greater than or equal to the 66th percentile. Developed ACD was identified based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.
Results: During 32,926.90 person-years, 106 individuals developed ACD in up to 8 years of follow-up. The study participants were separated into four categories by the top tertiles of hs-CRP and HbA1c based on the 66th percentile: high levels of both hs-CRP and HbA1c, only high levels of hs-CRP, only high levels of HbA1c, and non-high levels of hs-CRP nor HbA1c. Those who with a high level of only hs-CRP had the higher hazard for developing ACD (adjusted HR = 2.58; 95% CI = 1.29 ~ 5.17; P = 0.007), followed by the group with a high level of only HbA1c (adjusted HR = 2.52; 95% CI = 1.34 ~ 4.74; P = 0.004) and the group with high levels of both hs-CRP and HbA1c (adjusted HR = 2.36; 95% CI = 1.20 ~ 4.62; P = 0.012). Among those aged less than 65 years, hs-CRP was the only significant predictor of ACD risk (P = 0.046), whereas it did not yield any significant result in the elderly.
Conclusions: A higher risk of developing ACD was found not only in patients with high levels of inflammation but also high levels of glycated hemoglobin. Future studies should focus on the clinical implementation of hs-CRP or HbA1c to monitor cognitive deficits.
Journal: Journal of Surgical Oncology

February/17/2022
Background: Increasing attention has been drawn the prognostic value of inflammatory indices for colorectal cancer (CRC). However, the prognostic value of the preoperative C-reactive protein to prealbumin ratio (CPAR) in CRC remains unclear.
Methods: A retrospective study was conducted with 794 patients who had CRC and underwent radical surgical resection. The predictive performance of the inflammatory indices was analyzed and compared using the area under the time-dependent receiver operating characteristic curve. A competing risk regression model and Cox proportional hazard model were used to analyze the effects of CPAR on disease-free survival (DFS) and overall survival (OS), respectively.
Results: Patients with high CPAR (>7.25) had poor survival outcome. The CPAR had the best predictive performance among all inflammatory indices, and was significantly associated with several characteristics of tumor invasion, including histological grade, tumor stage, and tumor size. Multivariate analysis showed that high CPAR was independently associated with poor DFS (subdistribution hazard ratio = 2.28, 95% confidence interval [CI]: 1.74-2.82) and OS (hazard ratio = 1.78, 95% CI: 1.60-1.96).
Conclusion: Preoperative CPAR assessment could serve as an effective and reliable tool for prognostic prediction in patients with resectable CRC.

C Reactive Protein antibody

70R-49594 Fitzgerald 100 ul 292.8 EUR

C Reactive Protein Antibody

R30203 NSJ Bioreagents 100 ug 356.15 EUR

Cow C Reactive Protein (CRP) Protein

20-abx167834 Abbexa
  • 811.20 EUR
  • 343.20 EUR
  • 2498.40 EUR
  • 961.20 EUR
  • 577.20 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Pig C Reactive Protein (CRP) Protein

20-abx065615 Abbexa
  • 693.60 EUR
  • 309.60 EUR
  • 2064.00 EUR
  • 828.00 EUR
  • 510.00 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat C Reactive Protein (CRP) Protein

20-abx065613 Abbexa
  • 427.20 EUR
  • 260.40 EUR
  • 1161.60 EUR
  • 526.80 EUR
  • 343.20 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Active C Reactive Protein (CRP)

4-APA821Hu01 Cloud-Clone
  • 765.12 EUR
  • 328.80 EUR
  • 2539.20 EUR
  • 926.40 EUR
  • 1732.80 EUR
  • 588.00 EUR
  • 6168.00 EUR
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg

C Reactive Protein Rabbit mAb

A19003-100ul Abclonal 100 ul 492 EUR

C Reactive Protein Rabbit mAb

A19003-200ul Abclonal 200 ul 685.2 EUR

C Reactive Protein Rabbit mAb

A19003-20ul Abclonal 20 ul 265.2 EUR

C Reactive Protein Rabbit mAb

A19003-50ul Abclonal 50 ul 344.4 EUR

Native C Reactive Protein (CRP)

4-NPA821Hu02 Cloud-Clone
  • 442.56 EUR
  • 242.40 EUR
  • 1329.60 EUR
  • 523.20 EUR
  • 926.40 EUR
  • 372.00 EUR
  • 3144.00 EUR
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg

C Reactive Protein Rabbit pAb

E2380958 EnoGene 100ul 225 EUR

Active C Reactive Protein (CRP)

RPU55604-100ug Biomatik Corporation 100ug 950.4 EUR

Active C Reactive Protein (CRP)

RPU55604-1mg Biomatik Corporation 1mg 3744 EUR

Active C Reactive Protein (CRP)

RPU55604-50ug Biomatik Corporation 50ug 576 EUR

Native C Reactive Protein (CRP)

RPU56090-100ug Biomatik Corporation 100ug 475.2 EUR

Native C Reactive Protein (CRP)

RPU56090-1mg Biomatik Corporation 1mg 1872 EUR

Native C Reactive Protein (CRP)

RPU56090-50ug Biomatik Corporation 50ug 299.2 EUR

Human C Reactive Protein (CRP) Protein

20-abx168571 Abbexa
  • 326.40 EUR
  • 226.80 EUR
  • 727.20 EUR
  • 360.00 EUR
  • 276.00 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human C Reactive Protein (CRP) Protein

20-abx065612 Abbexa
  • 493.20 EUR
  • 260.40 EUR
  • 1328.40 EUR
  • 577.20 EUR
  • 360.00 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse C Reactive Protein (CRP) Protein

20-abx065617 Abbexa
  • 644.40 EUR
  • 292.80 EUR
  • 1863.60 EUR
  • 760.80 EUR
  • 477.60 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Sheep C Reactive Protein (CRP) Protein

20-abx652717 Abbexa
  • 777.60 EUR
  • 326.40 EUR
  • 2331.60 EUR
  • 910.80 EUR
  • 560.40 EUR
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
Journal: BMC Prim Care

February/17/2022
Background: The use of C-reactive protein (CRP) tests has been shown to safely reduce antibiotic prescribing for acute respiratory tract infections (RTIs). The aim of this study was to explore patient and clinical factors associated with the use of CRP testing when prescribing antibiotics recommended for RTIs.
Methods: A nation-wide retrospective cross-sectional register-based study based on first redeemed antibiotic prescriptions issued to adults in Danish general practice between July 2015 and June 2017. Only antibiotics recommended for treatment of RTIs were included in the analysis (penicillin-V, amoxicillin, co-amoxicillin or roxithromycin/clarithromycin). Logistic regression models were used to estimate odds ratios for patient-related and clinical factors on performing a CRP test in relation to antibiotic prescribing.
Results: A total of 984,149 patients redeemed at least one antibiotic prescription during the two-year period. About half of these prescriptions (49.6%) had an RTI stated as the indication, and a CRP test was performed in relation to 45.2% of these scripts. Lower odds of having a CRP test performed in relation to an antibiotic prescription was found for patients aged 75 years and above (OR 0.82, 95CI 0.79-0.86), with a Charlson Comorbidity Index of more than one (OR 0.93, 95CI 0.91-0.95), unemployed or on disability pension (OR 0.84, 95CI 0.83-0.85) and immigrants (OR 0.91, 95CI 0.88-0.95) or descendants of immigrants (OR 0.90, 95CI 0.84-0.96). Living with a partner (OR 1.08, 95CI 1.07-1.10), being followed in practice for a chronic condition (OR 1.22, 95CI 1.18-1.26) and having CRP tests performed in the previous year (OR 1.78, 95CI 1.73-1.84) were associated with higher odds of CRP testing in relation to antibiotic prescribing.
Conclusions: Differences were observed in the use of CRP tests among subgroups of patients indicating that both sociodemographic factors and comorbidity influence the decision to use a CRP test in relation to antibiotic prescriptions in general practice. Potentially, this means that the use of CRP tests could be optimised to increase diagnostic certainty and further promote rational prescribing of antibiotics. The rationale behind the observed differences could be further explored in future qualitative studies.

Leave a Reply

Your email address will not be published.